Studying two drugs before surgery for triple-negative breast cancer
Part of Cancer clinical trials.
This trial is testing whether giving a combination of two medicines before surgery can help shrink or eliminate tumors in people with triple-negative breast cancer (a type of breast cancer that lacks certain receptors). The goal is to see if this approach improves outcomes compared to the usual approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer that has not spread to distant parts of your body (stage II or III).
- Your tumor tests negative for estrogen, progesterone, and HER2 receptors.
- You have not had any prior treatment for this breast cancer (like chemotherapy, radiation, or surgery).
- You are generally healthy enough to participate (able to do daily activities, with adequate blood cell counts and organ function).
- You have a tissue sample from your tumor available for testing.
- You have not had certain prior treatments, like immune checkpoint inhibitors or Trop-2-targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This trial tests whether giving a targeted drug before surgery can help shrink early-stage triple-negative breast cancer tumors. It may be an option for people who have not yet had any treatment for their breast cancer.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
This trial tests a combination of two drugs given before surgery for early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink tumors and improve outcomes while possibly reducing the need for more intensive treatment.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.